The Costly Controversy of PrEP

This chapter explores the complex issues around the patenting and pricing of PrEP medications like Truvada and Descovy, highlighting the ongoing debates over access and affordability. Activists raise concerns about Gilead's monopolistic practices and the implications of high drug prices for those at risk of HIV. The discussion also touches on government initiatives aimed at increasing access for the uninsured, amidst challenges faced by underinsured individuals.